MANKIND PHARMA
Quarterly Results Analysis [Dec2023]
MANKIND PHARMA Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,607 Cr | ₹2,708 Cr | ₹2,579 Cr | ₹2,053 Cr | ₹2,091 Cr | ₹2,426 Cr | ₹2,180 Cr | ₹1,726 Cr |
Expenses | ₹2,000 Cr | ₹2,025 Cr | ₹1,924 Cr | ₹1,636 Cr | ₹1,654 Cr | ₹1,835 Cr | ₹1,724 Cr | ₹1,441 Cr |
Operating Income | ₹607 Cr | ₹683 Cr | ₹655 Cr | ₹417 Cr | ₹437 Cr | ₹591 Cr | ₹456 Cr | ₹285 Cr |
Other Income | ₹70 Cr | ₹60 Cr | ₹59 Cr | ₹48 Cr | ₹37 Cr | ₹27 Cr | ₹17 Cr | ₹34 Cr |
Interest | ₹9 Cr | ₹9 Cr | ₹6 Cr | ₹5 Cr | ₹13 Cr | ₹10 Cr | ₹16 Cr | ₹13 Cr |
Depreciation | ₹110 Cr | ₹96 Cr | ₹87 Cr | ₹85 Cr | ₹85 Cr | ₹79 Cr | ₹78 Cr | ₹47 Cr |
Profit Before Tax | ₹558 Cr | ₹638 Cr | ₹620 Cr | ₹375 Cr | ₹377 Cr | ₹529 Cr | ₹378 Cr | ₹258 Cr |
Profit After Tax | ₹455 Cr | ₹508 Cr | ₹489 Cr | ₹291 Cr | ₹293 Cr | ₹419 Cr | ₹294 Cr | ₹188 Cr |
EPS | ₹11.33 | ₹12.51 | ₹12.15 | ₹7.13 | ₹7.09 | ₹10.48 | ₹7.30 | ₹4.74 |
Industry Peers & Returns | 1W | 1M | 1Y |
MANKIND PHARMA | 1.3% | 7% | NA |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
CIPLA | 4.1% | -4.8% | 55.6% |
DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
LUPIN | 0.6% | 0.5% | 127.2% |
AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
MANKIND PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -3.73 % |
Y-o-Y | 24.68 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹2,607 Cr | -3.73 | |
Sep2023 | ₹2,708 Cr | 5.02 | |
Jun2023 | ₹2,579 Cr | 25.62 | |
Mar2023 | ₹2,053 Cr | -1.83 | |
Dec2022 | ₹2,091 Cr | -13.81 | |
Sep2022 | ₹2,426 Cr | 11.28 | |
Jun2022 | ₹2,180 Cr | 26.32 | |
Mar2022 | ₹1,726 Cr | - |
MANKIND PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -11.15 % |
Y-o-Y | 38.78 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹607 Cr | -11.15 | |
Sep2023 | ₹683 Cr | 4.25 | |
Jun2023 | ₹655 Cr | 57.15 | |
Mar2023 | ₹417 Cr | -4.66 | |
Dec2022 | ₹437 Cr | -26.01 | |
Sep2022 | ₹591 Cr | 29.48 | |
Jun2022 | ₹456 Cr | 60.17 | |
Mar2022 | ₹285 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -7.74 % |
Y-o-Y | 11.29 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 23.26% | -7.74 | |
Sep2023 | 25.21% | -0.71 | |
Jun2023 | 25.39% | 25.07 | |
Mar2023 | 20.3% | -2.87 | |
Dec2022 | 20.9% | -14.17 | |
Sep2022 | 24.35% | 16.34 | |
Jun2022 | 20.93% | 26.85 | |
Mar2022 | 16.5% | - |
MANKIND PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -10.34 % |
Y-o-Y | 55.17 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹455 Cr | -10.34 | |
Sep2023 | ₹508 Cr | 3.73 | |
Jun2023 | ₹489 Cr | 68.24 | |
Mar2023 | ₹291 Cr | -0.83 | |
Dec2022 | ₹293 Cr | -29.95 | |
Sep2022 | ₹419 Cr | 42.37 | |
Jun2022 | ₹294 Cr | 56.77 | |
Mar2022 | ₹188 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -6.88 % |
Y-o-Y | 24.45 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 17.46 % | -6.88 | |
Sep2023 | 18.75 % | -1.21 | |
Jun2023 | 18.98 % | 33.94 | |
Mar2023 | 14.17 % | 1.00 | |
Dec2022 | 14.03 % | -18.71 | |
Sep2022 | 17.26 % | 27.95 | |
Jun2022 | 13.49 % | 24.10 | |
Mar2022 | 10.87 % | - |
MANKIND PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -9.43 % |
Y-o-Y | 59.80 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹11.33 | -9.43 | |
Sep2023 | ₹12.51 | 2.96 | |
Jun2023 | ₹12.15 | 70.41 | |
Mar2023 | ₹7.13 | 0.56 | |
Dec2022 | ₹7.09 | -32.35 | |
Sep2022 | ₹10.48 | 43.56 | |
Jun2022 | ₹7.3 | 54.01 | |
Mar2022 | ₹4.74 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD